The application period for the 2017 Sartorius & Science Prize for Regenerative Medicine & Cell Therapy ended on October 1st 2017. We are thrilled to see the attention it generated in the scientific community. Currently, there is an ongoing screening process conducted by a panel of experts assembled by the American Association for the Advancement of Science (AAAS).
The winner and finalist will officially be announced on March 8th 2018 by AAAS/Science. Sartorius is very much looking forward to meeting these outstanding scientists at our Research Xchange Forum on Trends and Challenges on Regenerative Medicine & Cell Therapy, March 20-21, 2018 in Goettingen, Germany.
If you missed your chance to apply, we have good news for you! The next application period will be open between April 1st and October 1st 2018.
Use this outstanding opportunity to introduce your research and yourself to the world!
Are you a representative of the upcoming generation of thought leaders in your field? Together we look forward to your application for the new Sartorius & Science Prize in Regenerative Medicine and Cell Therapy.
The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is an annual prize geared towards researchers focused on basic or translational research that advances regenerative medicine and cell therapy. Established in 2017, the prize is awarded for outstanding research performed by the applicant and as a mutual endeavour to raise awareness for the field and its fundamental significance for our future.
The winner of the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is awarded US$25,000 and a publication of his or her essay in Science. This Grand Prize essay and those of up to three runners-up are also published on Science Online. The winner and the runners-up are invited to the award ceremony. Furthermore, a 5-year AAAS membership and online subscription to Science, accompanied by attractive product packages from Sartorius, are awarded!
Entries can be made in the fields of regenerative medicine, cell therapy, gene therapy, immunotherapy as well as materials and tissue engineering.
Every individual scientist who received his or her PhD|MD within the past 10 years may apply.
Please submit a 1,000-word essay describing your research and its implications for regenerative medicine and cell immunotherapy as well as supporting documents.
April 1st until October 1st 2018
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions (BPS) and Lab Products & Services (LPS).
Biopharmaceuticals are manufactured using living cells in complex, lengthy and expensive procedures. BPS focuses on single-use solutions which help customers produce biotech medications and vaccines safely and efficiently. In fact, Sartorius has been pioneering and setting the standard for single-use products which are extensively used in all biopharmaceutical manufacturing processes.
Backed by an extensive offering of premium laboratory instruments, consumables and services, the LPS division concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those in academic research institutes. Through strategic acquisitions, our portfolio was further developed to suit the emerging needs and complexities of the regenerative medicine and cell therapy industry. LPS’s innovative bioanalytical tools help scientists answer fundamental and complex biological questions. Sartorius focuses on fast, multiplex cell, protein and virus analysis quantification, on the end-to-end production platforms for cell expansion and harvesting, and on the crucial safety aspects of quality control.
Founded in 1870, Sartorius earned sales revenue of more than 1.3 billion euros in 2016. Approximately 7,000 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.
The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society, and publisher of the journals, Science, Science Translational Medicine, Science Signaling, Science Advances, Science Immunology, and Science Robotics. AAAS was founded in 1848, and includes some 254 affiliated societies and academies of science, serving 10 million individuals. Science, founded by Thomas Edison, has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of more than 400,000.
The non-profit AAAS — www.aaas.org — is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy, international programs, science education, and more. Science's daily online news is always free to the public, as are editorials, any paper with broad public health significance, and all research articles 12 months after publication. Science further participates in various efforts to provide free access for scientists in the world's poorest countries.